FNY Managed Accounts’s Biogen BIIB Stock Holding History

FNY Managed Accounts’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-310	Closed	-$107K	–	308
2016 Q1	$107K	Buy	+310	New	+$81.9K	0.19%	92

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

FNY Managed Accounts's BIIB Position: Q2 2017 in Review

FNY Managed Accounts sold out of Biogen (BIIB) in Q2 2017, closing a stake of 130 shares — an estimated $35K sold.

FNY Managed Accounts first reported a position in BIIB in Q1 2014 and held it in 3 quarters. The position peaked at $807K in Q1 2016. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

FNY Managed Accounts reported no remaining Biogen position as of Q2 2017 after selling out during the quarter.
FNY Managed Accounts sold 130 Biogen shares in Q2 2017, an estimated $35K.
FNY Managed Accounts first reported a position in Biogen in Q1 2014 and held it in 3 quarters.
FNY Managed Accounts's Biogen position peaked at $807K in Q1 2016.
992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on FNY Managed Accounts's 13F filing for Q2 2017, filed 10 Aug 2017.